Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Earlier this year, the FDA officially moved semaglutide, including popular versions like Ozempic and Wegovy, off of its ... pointing to a 10-page chart that the plaintiffs created.

LifeMD's stock has roughly tripled in 2025 as its telehealth business is delivering stellar revenue growth. Click for my ...

Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Valuation also favors CVS. While UNH trades at a forward P/E of 12.98X, CVS trades at a more modest 10.31. This valuation gap ...